All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Cibus Inc, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Nalbuphine ER
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Cibus Inc, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Nalbuphine ER appears in 1 tracked Healthcare story from March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Nalbuphine ER. Shared-story counts are live from our verified record — not editorial picks.
Trevi Therapeutics reported significant strategic progress in its Q4 2025 earnings, focusing on the clinical development of Haduvio for chronic cough in IPF. While the company achieves key R&D milestones, the broader biotech sector continues to navigate a complex financial landscape characterized by high capital costs and strategic realignments.